T ‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial

Relationship Between Bone Mineral Density T‐score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

(2019) S Ferrari et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

(2019) Mary L Bouxsein et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

(2018) Michael R McClung et al.   JOURNAL OF BONE AND MINERAL RESEARCH

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

(2018) Felicia Cosman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study

(2018) E Michael Lewiecki et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

(2017) Kenneth G. Saag et al.   NEW ENGLAND JOURNAL OF MEDICINE

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

(2016) Felicia Cosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?

(2014) Felicia Cosman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

(2014) Michael R. McClung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

(2011) Matthew Austin et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH